[go: up one dir, main page]

AR092982A1 - Modulacion de la expresion de receptores androgenicos - Google Patents

Modulacion de la expresion de receptores androgenicos

Info

Publication number
AR092982A1
AR092982A1 ARP130103693A ARP130103693A AR092982A1 AR 092982 A1 AR092982 A1 AR 092982A1 AR P130103693 A ARP130103693 A AR P130103693A AR P130103693 A ARP130103693 A AR P130103693A AR 092982 A1 AR092982 A1 AR 092982A1
Authority
AR
Argentina
Prior art keywords
androgen
receivers
modulation
expression
proliferation
Prior art date
Application number
ARP130103693A
Other languages
English (en)
Inventor
A Macleod Robert
Kim Youngsoo
Monia Brett
Swayze Eric
Seth Punit
Zhou Tianyuan
M Freier Susan
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50475891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR092982(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of AR092982A1 publication Critical patent/AR092982A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)

Abstract

Ciertas realizaciones se refieren a compuestos y composiciones que tienen como diana un receptor androgénico (RA) humano para inhibir los niveles del receptor androgénico en una célula, lo cual puede resultar útil en métodos de tratamiento del cáncer y de inhibición del crecimiento o la proliferación de células cancerosas.
ARP130103693A 2012-10-11 2013-10-10 Modulacion de la expresion de receptores androgenicos AR092982A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261712756P 2012-10-11 2012-10-11
US201261712780P 2012-10-11 2012-10-11
US201261723701P 2012-11-07 2012-11-07
US201361777851P 2013-03-12 2013-03-12
US201361777813P 2013-03-12 2013-03-12
US201361777895P 2013-03-12 2013-03-12

Publications (1)

Publication Number Publication Date
AR092982A1 true AR092982A1 (es) 2015-05-13

Family

ID=50475891

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103693A AR092982A1 (es) 2012-10-11 2013-10-10 Modulacion de la expresion de receptores androgenicos

Country Status (32)

Country Link
US (3) US9175291B2 (es)
EP (1) EP2906226B1 (es)
JP (2) JP6306598B2 (es)
KR (1) KR102124228B1 (es)
CN (2) CN108300718B (es)
AP (1) AP2015008368A0 (es)
AR (1) AR092982A1 (es)
AU (2) AU2013329070A1 (es)
BR (1) BR112015007878A2 (es)
CA (1) CA2887867C (es)
CL (1) CL2015000901A1 (es)
CO (1) CO7400882A2 (es)
DK (1) DK2906226T3 (es)
DO (1) DOP2015000083A (es)
EC (1) ECSP15012462A (es)
ES (1) ES2706387T3 (es)
HK (2) HK1213774A1 (es)
IL (2) IL237855A0 (es)
MX (1) MX369207B (es)
NI (1) NI201500051A (es)
NZ (1) NZ706151A (es)
PE (1) PE20150722A1 (es)
PH (1) PH12015500788A1 (es)
PL (1) PL2906226T3 (es)
PT (1) PT2906226T (es)
RU (1) RU2670486C9 (es)
SG (1) SG11201502505UA (es)
TN (1) TN2015000140A1 (es)
TW (1) TW201420594A (es)
UY (1) UY35078A (es)
WO (1) WO2014059238A2 (es)
ZA (1) ZA201503203B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9517229B2 (en) 2011-07-29 2016-12-13 Medivation Prostate Therapeutics, Inc. Treatment of breast cancer
MY193914A (en) 2012-03-05 2022-11-01 Oy Arctic Partners Ab Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
AR092982A1 (es) * 2012-10-11 2015-05-13 Isis Pharmaceuticals Inc Modulacion de la expresion de receptores androgenicos
PE20170298A1 (es) 2014-03-28 2017-04-18 Opko Diagnostics Llc Composiciones y metodos relacionados con el diagnostico del cancer de prostata
EP3230471B1 (en) 2014-12-12 2019-08-28 Medivation Prostate Therapeutics LLC Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
US10426789B2 (en) 2015-02-26 2019-10-01 Ionis Pharmaceuticals, Inc. Allele specific modulators of P23H rhodopsin
MX2017012320A (es) 2015-03-27 2018-01-18 Opko Diagnostics Llc Estandares de antigeno prostatico y sus usos.
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
CN105492632B (zh) * 2015-07-01 2021-08-06 深圳市第二人民医院 一种检测与特发性无精子症相关的遗传标记的引物对
US11116843B2 (en) 2015-09-25 2021-09-14 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
WO2017066697A1 (en) * 2015-10-14 2017-04-20 Dou Qingping Treatments and diagnostics for cancers
CN105541991B (zh) * 2015-12-16 2019-05-31 中国医科大学 Bap18在促进前列腺癌方面的应用
US10604759B2 (en) * 2016-01-15 2020-03-31 City Of Hope Targeting glioblastoma stem cells through the TLX-TET3 axis
WO2017143000A1 (en) * 2016-02-18 2017-08-24 Ionis Pharmaceuticals, Inc. Modulators of klk3 erna
WO2017207702A1 (en) * 2016-06-02 2017-12-07 Sint-Augustinus Androgen receptor splice variants and androgen deprivation therapy
EP4035659A1 (en) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes for delivery of therapeutic agents
US10933134B2 (en) * 2017-03-16 2021-03-02 Memorial Sloan Kettering Cancer Center Combination therapies for treatment of cancer
EP3752612A4 (en) 2018-02-12 2021-11-10 Ionis Pharmaceuticals, Inc. MODIFIED COMPOUNDS AND USES THEREOF
EP3775172A4 (en) * 2018-03-26 2021-12-29 Duke University Splice-switching oligonucleotides and methods of use
CN109321569B (zh) * 2018-10-29 2022-04-12 迈杰转化医学研究(苏州)有限公司 一种引物探针组合物及其应用
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
US20220002723A1 (en) * 2018-11-14 2022-01-06 Board Of Regents, The University Of Texas System Methods for the treatment of small round cell tumors
KR102473989B1 (ko) 2018-11-28 2022-12-07 (주)바이오니아 안드로젠 수용체 특이적 서열을 포함하는 이중나선 올리고뉴클레오티드 구조체, 및 이를 포함하는 탈모 예방 및 발모용 조성물
WO2020148400A1 (en) * 2019-01-16 2020-07-23 Stichting Katholieke Universiteit Antisense oligonucleotides for use in the treatment of crpc
CN109880931A (zh) * 2019-04-11 2019-06-14 江苏省农业科学院 一种丝瓜抗黄瓜花叶病毒cmv主效qtl的slaf-snp分子标记方法及应用
WO2021021885A1 (en) * 2019-07-29 2021-02-04 The Medical College Of Wisconsin, Inc. Methods of treating advanced prostate cancer
EP4054655A4 (en) * 2019-11-08 2024-02-28 Ionis Pharmaceuticals, Inc. COMPOUNDS AND METHODS FOR REDUCING SPDEF EXPRESSION
CN116270710B (zh) * 2023-02-16 2025-01-28 南方医科大学珠江医院 circRBM33作为靶点在前列腺癌诊断和治疗中的应用

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2699808A (en) 1944-10-06 1955-01-18 Mark W Lowe Apparatus for peeling tomatoes
US2699508A (en) 1951-12-21 1955-01-11 Selectronics Inc Method of mounting and construction of mounting for low frequency piezoelectric crystals
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
DK0497875T3 (da) 1989-10-24 2000-07-03 Gilead Sciences Inc 2'-modificerede oligonukleotider
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
DE69032425T2 (de) 1990-05-11 1998-11-26 Microprobe Corp., Bothell, Wash. Teststreifen zum Eintauchen für Nukleinsäure-Hybridisierungsassays und Verfahren zur kovalenten Immobilisierung von Oligonucleotiden
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US5877160A (en) 1991-05-31 1999-03-02 Genta Incorporated Compositions and methods of treatment of androgen-associated baldness using antisense oligomers
US7517644B1 (en) 1991-08-23 2009-04-14 Larry J. Smith Method and compositions for cellular reprogramming
DE59208572D1 (de) 1991-10-17 1997-07-10 Ciba Geigy Ag Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
FR2687679B1 (fr) 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
EP0577558A2 (de) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
JPH08504559A (ja) 1992-12-14 1996-05-14 ハネウエル・インコーポレーテッド 個別に制御される冗長巻線を有するモータシステム
AU692148B2 (en) 1993-02-19 1998-06-04 Genta Incorporated Treatment of androgen-associated baldness using antisense oligomers
DE69404289T2 (de) 1993-03-30 1998-02-19 Sanofi Sa Acyclische nucleosid analoge und sie enthaltende oligonucleotidsequenzen
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5556956A (en) 1993-11-04 1996-09-17 Board Of Regents, The University Of Texas System Methods and compositions relating to the androgen receptor gene and uses thereof
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
CA2239976A1 (en) 1995-09-20 1997-03-27 Paul A. Zamecnik Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate
US6300060B1 (en) 1995-11-09 2001-10-09 Dana-Farber Cancer Institute, Inc. Method for predicting the risk of prostate cancer morbidity and mortality
US5656408A (en) 1996-04-29 1997-08-12 Xerox Corporation Coated carrier particles
US6489163B1 (en) 1996-05-08 2002-12-03 Board Of Regents, The University Of Texas System Ribozyme mediated inactivation of the androgen receptor
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
US5994076A (en) 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
DE69829760T3 (de) 1997-09-12 2016-04-14 Exiqon A/S Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US20030228597A1 (en) 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
US6043352A (en) 1998-08-07 2000-03-28 Isis Pharmaceuticals, Inc. 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
AU5723199A (en) 1998-09-15 2000-04-03 Signalgene Inc. Marker at the androgen receptor gene for determining breast cancer susceptibility
BR0009884A (pt) 1999-04-21 2002-01-08 American Home Prod Processos e composições para a inibição da função das sequências de polinucleotìdeos
NZ514348A (en) 1999-05-04 2004-05-28 Exiqon As L-ribo-LNA analogues
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
ATE322493T1 (de) 1999-12-30 2006-04-15 Leuven K U Res & Dev Cyclohexennukleinsäuren
US6255110B1 (en) 2000-01-21 2001-07-03 Isis Pharmaceuticals, Inc. Antisense modulation of ARA70 expression
WO2001073116A2 (en) 2000-03-28 2001-10-04 Signalgene Inc. Method for determining osteoporosis susceptibility and/or low bone density and reagents therefor
AU2001250572A1 (en) 2000-04-07 2001-10-23 Epigenomics Ag Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations
WO2001083740A2 (en) 2000-05-04 2001-11-08 Avi Biopharma, Inc. Splice-region antisense composition and method
IL152719A0 (en) 2000-06-28 2003-06-24 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification
WO2002000716A2 (en) 2000-06-28 2002-01-03 Bristol-Myers Squibb Company Cell lines and cell-based assays for identification of androgen receptor modulators
RU2003102390A (ru) * 2000-06-28 2004-05-27 Бристол-Маерс Сквибб Компани (Us) Селективные модуляторы рецептора андрогена и способы их идентификации, изготовления и применения
WO2002010452A2 (en) 2000-07-27 2002-02-07 University Of Rochester Methods and compositions for predicting prostate cancer
US20020165381A1 (en) 2000-11-30 2002-11-07 Isabelle Ahrens-Fath Human androgen receptor variants
JP2002247986A (ja) 2001-02-23 2002-09-03 Mitsui Chemicals Inc 性ホルモン受容体作用評価に有用な細胞
US20070021360A1 (en) 2001-04-24 2007-01-25 Nyce Jonathan W Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase
US20050159376A1 (en) 2002-02-20 2005-07-21 Slrna Therapeutics, Inc. RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
JP2005504020A (ja) 2001-07-03 2005-02-10 アイシス・ファーマシューティカルス・インコーポレーテッド ヌクレアーゼ耐性キメラオリゴヌクレオチド
US6680342B2 (en) 2001-09-20 2004-01-20 Mayo Foundation For Medical Education And Research Methods and compositions for inhibiting the proliferation of prostate cancer cells
FR2832154B1 (fr) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
JP2004008140A (ja) 2002-06-10 2004-01-15 Sumitomo Chem Co Ltd 変異型アンドロゲンレセプターおよびその活性評価用細胞
EP1540004A4 (en) 2002-07-31 2007-10-03 Nucleonics Inc DOUBLE-STRING RNA STRUCTURES AND CONSTRUCTS AND METHOD FOR THE PRODUCTION AND USE THEREOF
CA2502649A1 (en) 2002-10-18 2004-04-29 Nucleonics Inc. Double-stranded rna structures and constructs, and methods for generating and using the same
WO2004041277A1 (en) 2002-11-01 2004-05-21 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
EP1562971B1 (en) 2002-11-05 2014-02-12 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US8604183B2 (en) 2002-11-05 2013-12-10 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
PT2284266E (pt) * 2002-11-14 2013-12-17 Thermo Fisher Scient Biosciences Inc Siarn contra tp53
US6673661B1 (en) 2002-12-20 2004-01-06 Taiwan Semiconductor Manufacturing Co., Ltd. Self-aligned method for forming dual gate thin film transistor (TFT) device
AU2004204068B8 (en) 2003-01-03 2010-03-25 Gencia Corporation SiRNA Mediated Post - Transcriptional Gene Silencing of Genes involved in Alopecia
MXPA05007605A (es) 2003-01-17 2005-09-30 Warner Lambert Co Antagonista del receptor de androgenos.
JP2004254600A (ja) 2003-02-26 2004-09-16 Sumitomo Chem Co Ltd 変異型アンドロゲンレセプターおよびその活性評価用細胞
JP2004254601A (ja) 2003-02-26 2004-09-16 Sumitomo Chem Co Ltd 変異型アンドロゲンレセプターおよびその活性評価用細胞
DE10322108B4 (de) 2003-05-09 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Antiandrogene Pyrrolidine mit tumorhemmender Wirksamkeit
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
WO2005021570A1 (ja) 2003-08-28 2005-03-10 Gene Design, Inc. Ｎ−０結合性架橋構造型新規人工核酸
JP5379347B2 (ja) 2003-09-18 2013-12-25 アイシス ファーマシューティカルズ， インコーポレーテッド ４’−チオヌクレオシドおよびオリゴマー化合物
US20050164970A1 (en) 2003-12-22 2005-07-28 University Of Kansas Medical Center Method for treating prostate cancer using siRNA duplex for androgen receptor
US20050244851A1 (en) 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
WO2005080410A1 (en) 2004-02-20 2005-09-01 Genesis Research And Development Corporation Limited Targeted delivery of rna interference molecules for the treatment of ige-mediated disorders
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
JPWO2005116204A1 (ja) 2004-05-11 2008-06-19 株式会社アルファジェン Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法
CA2566942A1 (en) 2004-05-17 2005-12-08 Acadia Pharmaceuticals Inc. Androgen receptor modulators and method of treating disease using the same
DE102004025881A1 (de) 2004-05-19 2006-01-05 Beiersdorf Ag Oligoribonukleotide zur Beeinflussung des Haarwachstums
EP1765415A4 (en) 2004-06-03 2010-03-24 Isis Pharmaceuticals Inc OLIGOMER COMPOUNDS TO FACILITATE RISC LOADING
EP1791567B1 (en) 2004-08-10 2015-07-29 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
US20080261905A1 (en) 2004-11-08 2008-10-23 K.U. Leuven Research And Development Modified Nucleosides for Rna Interference
WO2006086345A2 (en) 2005-02-07 2006-08-17 The Trustees Of Columbia University In The City Of New York Methods to treat or prevent hormone-resistant prostate cancer using sirna specific for protocadherin-pc, or other inhibitors of protocadherin-pc expression or activity
US8912317B2 (en) 2005-02-11 2014-12-16 International Business Machines Corporation Ribonucleic acid interference molecules of Arabidopsis thaliana
US8795987B2 (en) 2005-02-11 2014-08-05 International Business Machines Corporation Ribonucleic acid interference molecules of Oryza sativa
US20070154896A1 (en) 2005-02-11 2007-07-05 International Business Machines Corporation System and method for identification of MicroRNA target sites and corresponding targeting MicroRNA sequences
US20070213293A1 (en) 2005-04-08 2007-09-13 Nastech Pharmaceutical Company Inc. Rnai therapeutic for respiratory virus infection
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
US20070111227A1 (en) 2005-07-28 2007-05-17 Green Pamela J Small regulatory RNAs and methods of use
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CA2640171C (en) 2006-01-27 2014-10-28 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
JP4961549B2 (ja) 2006-02-16 2012-06-27 国立大学法人愛媛大学 アンドロゲン受容体遺伝子に特異的なｓｉＲＮＡ
US8178503B2 (en) 2006-03-03 2012-05-15 International Business Machines Corporation Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes
LT3100727T (lt) 2006-03-27 2018-12-10 The Regents Of The University Of California Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui
JP2007282598A (ja) 2006-04-19 2007-11-01 Japan Health Science Foundation 性分化異常症診断マーカー
CA2651453C (en) 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
JP4798093B2 (ja) 2006-08-04 2011-10-19 日産自動車株式会社 流体改質装置及びこれを用いた流体改質方法
AR055648A1 (es) 2006-09-21 2007-08-29 Gen Med Sa Un oligonucleotido de rna de doble cadena una composicion farmaceutica o cosmetica que lo comprende y uso del mismo enla preparacion de un medicamento para el tratamiento de enfermedades relacionadas con el metabolismo de androgenos
ES2391212T3 (es) 2006-12-07 2012-11-22 Novartis Ag Cribado genético prenatal no-invasivo
WO2008076918A2 (en) 2006-12-15 2008-06-26 University Of Maryland, Baltimore Anti-cancer agents and androgen inhibition activity compound
US20100190837A1 (en) 2007-02-15 2010-07-29 Isis Pharmaceuticals, Inc. 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom
US8461343B2 (en) 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
EP2170917B1 (en) 2007-05-30 2012-06-27 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
ES2376507T5 (es) 2007-07-05 2015-08-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos 6-disustituidos
MX2010003606A (es) * 2007-10-01 2010-07-02 Isis Pharmaceuticals Inc Modulacion antisentido de la expresion del receptor del factor de crecimiento fibroblastico 4.
US8546556B2 (en) 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
US8450290B2 (en) 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
JP5872162B2 (ja) 2007-11-26 2016-03-01 エンゾン ファーマシューティカルズ，インコーポレーテッド アンドロゲン受容体を標的化するｌｎａアンタゴニスト
KR20100099742A (ko) 2007-12-21 2010-09-13 아스트라제네카 아베 안드로겐 수용체 관련 병태의 치료에서 사용하기 위한 이환식 유도체
US8530640B2 (en) 2008-02-07 2013-09-10 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
US20110110923A1 (en) 2008-02-12 2011-05-12 The Brigham And Women's Hospital, Inc. Fish assay for eml4 and alk fusion in lung cancer
FR2929292A1 (fr) 2008-03-28 2009-10-02 Exonhit Therapeutics S A Sa Procede et methodes de diagnostic de la maladie d'alzheimer
US20090282496A1 (en) 2008-04-04 2009-11-12 University Of Rochester Medical Center Androgen Receptor Related Methods for Treating Bladder Cancer
WO2009128936A2 (en) 2008-04-16 2009-10-22 The Johns Hopkins University Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants
AU2009275387B2 (en) 2008-08-25 2010-07-08 Excaliard Pharmaceuticals, Inc. Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
US8133724B2 (en) 2008-09-17 2012-03-13 University Of Maryland, Baltimore Human androgen receptor alternative splice variants as biomarkers and therapeutic targets
DK2361256T3 (da) 2008-09-24 2013-07-01 Isis Pharmaceuticals Inc Cyclohexenyl-nukleinsyreanaloger
DK2356129T3 (da) 2008-09-24 2013-05-13 Isis Pharmaceuticals Inc Substituerede alpha-L-bicykliske nukleosider
US10927415B2 (en) 2008-11-26 2021-02-23 The Johns Hopkins University Methods for identifying cancer risk
US8202690B2 (en) 2008-11-28 2012-06-19 Hisamitsu Pharmaceutical Co., Inc. Cancer marker and therapeutic agent for cancer
WO2011005793A1 (en) 2009-07-06 2011-01-13 Alnylam Pharmaceuticals, Inc. Cell-based bioprocessing
CA2767207A1 (en) 2009-07-06 2011-01-13 Alnylam Pharmaceuticals, Inc. Bioprocessing
KR101819199B1 (ko) 2010-02-16 2018-01-16 아라곤 파마슈티컬스, 인코포레이티드 안드로겐 수용체 조절제 및 이의 용도
US20130130241A1 (en) 2010-03-08 2013-05-23 Regents Of The University Of Minnesota Androgen receptor isoforms and methods
US9068185B2 (en) 2010-03-12 2015-06-30 Sarepta Therapeutics, Inc. Antisense modulation of nuclear hormone receptors
WO2011139702A2 (en) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. Modified nucleosides and oligomeric compounds prepared therefrom
EP2576574A2 (en) 2010-05-28 2013-04-10 Sarepta Therapeutics, Inc. Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
WO2012005898A2 (en) 2010-06-15 2012-01-12 Alnylam Pharmaceuticals, Inc. Chinese hamster ovary (cho) cell transcriptome, corresponding sirnas and uses thereof
EP2591104A4 (en) * 2010-07-06 2014-09-03 Dicerna Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR SPECIFIC INHIBITION OF THE ANDROGEN RECEPTOR BY DOUBLE-STRUCTURED RNA
KR101900770B1 (ko) * 2010-07-19 2018-09-20 아이오니스 파마수티컬즈, 인코포레이티드 근육긴장성 이영양증-단백질 키나제(dmpk) 발현의 조절 방법
WO2012018881A2 (en) 2010-08-03 2012-02-09 Alnylam Pharmaceuticals, Inc. Methods and compositions for the regulation of rna
AU2011326034B2 (en) 2010-11-12 2016-02-04 Roche Innovation Center Copenhagen A/S Compositions and methods for treating androgen receptor dependent disorders including cancers
WO2012087983A1 (en) 2010-12-20 2012-06-28 The General Hospital Corporation Polycomb-associated non-coding rnas
HUE044178T4 (hu) 2011-02-02 2019-10-28 Excaliard Pharmaceuticals Inc Kötõszöveti növekedési faktort (CTGF) célzó antiszensz vegyületek keloidok vagy hipertrófiás hegek kezelési eljárásban történõ alkalmazásra
US10017764B2 (en) 2011-02-08 2018-07-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
WO2012120374A2 (en) * 2011-03-10 2012-09-13 Oslo Universitetssykehus Hf Methods and biomarkers for detection of gastrointestinal cancers
US10023861B2 (en) 2011-08-29 2018-07-17 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
EP2812342B1 (en) 2012-02-08 2017-11-15 Ionis Pharmaceuticals, Inc. Modulation of rna by repeat targeting
US9778706B2 (en) 2012-02-24 2017-10-03 Blackberry Limited Peekable user interface on a portable electronic device
US9984408B1 (en) 2012-05-30 2018-05-29 Amazon Technologies, Inc. Method, medium, and system for live video cooperative shopping
AR092982A1 (es) 2012-10-11 2015-05-13 Isis Pharmaceuticals Inc Modulacion de la expresion de receptores androgenicos

Also Published As

Publication number Publication date
JP2018126141A (ja) 2018-08-16
USRE48461E1 (en) 2021-03-09
MX369207B (es) 2019-10-31
MX2015004641A (es) 2015-07-14
IL237855A0 (en) 2015-05-31
US20140107180A1 (en) 2014-04-17
EP2906226B1 (en) 2018-11-21
CN108300718A (zh) 2018-07-20
AU2017200759B2 (en) 2018-07-19
IL262218B (en) 2020-08-31
CN104703610B (zh) 2018-03-23
KR20150064210A (ko) 2015-06-10
EP2906226A2 (en) 2015-08-19
CA2887867C (en) 2019-09-24
RU2015111672A (ru) 2016-12-10
RU2670486C9 (ru) 2019-04-01
JP6599497B2 (ja) 2019-10-30
CO7400882A2 (es) 2015-09-30
KR102124228B1 (ko) 2020-06-17
NZ706151A (en) 2018-11-30
CL2015000901A1 (es) 2016-02-26
US9175291B2 (en) 2015-11-03
US9567588B2 (en) 2017-02-14
HK1213774A1 (zh) 2016-07-15
EP2906226A4 (en) 2016-06-08
PL2906226T3 (pl) 2019-04-30
WO2014059238A2 (en) 2014-04-17
PE20150722A1 (es) 2015-06-03
ES2706387T3 (es) 2019-03-28
SG11201502505UA (en) 2015-04-29
IL262218A (en) 2018-11-29
CN104703610A (zh) 2015-06-10
ECSP15012462A (es) 2015-12-31
CN108300718B (zh) 2022-02-22
PT2906226T (pt) 2019-02-25
AU2017200759A1 (en) 2017-03-02
AP2015008368A0 (en) 2015-04-30
AU2013329070A1 (en) 2015-04-16
RU2670486C2 (ru) 2018-10-23
US20160068846A1 (en) 2016-03-10
TN2015000140A1 (en) 2016-10-03
UY35078A (es) 2014-03-31
JP6306598B2 (ja) 2018-04-04
DOP2015000083A (es) 2015-06-15
PH12015500788A1 (en) 2015-06-15
ZA201503203B (en) 2016-09-28
WO2014059238A3 (en) 2014-06-19
BR112015007878A2 (pt) 2017-11-28
HK1258404A1 (zh) 2019-11-08
NI201500051A (es) 2016-02-15
JP2016501513A (ja) 2016-01-21
DK2906226T3 (en) 2019-02-18
TW201420594A (zh) 2014-06-01
WO2014059238A8 (en) 2015-04-16
CA2887867A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
AR092982A1 (es) Modulacion de la expresion de receptores androgenicos
CL2017003456A1 (es) Metodos para tratar tumores de celulas epitelioides
PH12019502379A1 (en) Pd-1/pd-l1 inhibitors
MX2014001218A (es) Tratamiento de cancer de mama.
EA201390756A1 (ru) Модулирующие nk-клетки терапии и способы для лечения гематологических злокачественных заболеваний
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
CR20150316A (es) Compuestos y sus métodos de empleo
DOP2015000227A (es) Virus de la enfermedad de newcastle y usos de los mismos
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
UY35812A (es) ?loci de maíz óptimos?.
NI201500094A (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y métodos de tratamiento con los mismos.
MX2015003874A (es) Modulacion de ire1.
MX2015013686A (es) Composiciones y metodos para potenciar la estabilidad microbiana.
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX359769B (es) Metodos para descelularizar huesos.
MX2015013177A (es) Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki.
MX360774B (es) Antagonistas de progesterona.
IN2014KN02620A (es)
DK3460052T3 (da) Forbedrede allogene dendrittiske celler til anvendelse i behandling af cancer
MX2018004243A (es) Regimenes de dosificacion.
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer
CL2016002532A1 (es) Compuestos derivados de diheterociclo enlazado a cicloalquilo con actividad inhibidora de gls1 uso en el tratamiento de crecimiento celular anormal, tal como cáncer composición farmacéutica que los contiene
MX2015013021A (es) 5-bromo-indirrubinas.

Legal Events

Date Code Title Description
FB Suspension of granting procedure